Bristol Myers Squibb's ZENBEXUS Combination Therapy Shows Superior Survival in Multiple Myeloma Trial

  • Bristol Myers Squibb's ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd) demonstrated a 51% reduction in the risk of disease progression or death compared to standard of care in relapsed/refractory multiple myeloma.
  • The Phase 3 EXCALIBER-RRMM study showed median progression-free survival of 42 months for ZDd vs. 20 months for the standard regimen.
  • Results were presented at the International Myeloma Society's 23rd annual meeting and published in Lancet Oncology.
  • ZENBEXUS is currently approved under accelerated approval contingent on confirmatory trial results.
  • The study included 800 patients with a median follow-up of 23 months.

This positive Phase 3 result reinforces Bristol Myers Squibb's leadership in multiple myeloma treatment, particularly in the relapsed/refractory space. The combination therapy's superior progression-free survival could reshape treatment paradigms, potentially capturing market share from existing regimens. The company's targeted protein degradation platform continues to yield promising clinical outcomes, positioning it as a key player in oncology innovation.

Regulatory Pathway
Whether the positive Phase 3 results will lead to full approval and expanded indications for ZENBEXUS beyond the current accelerated approval.
Market Positioning
How Bristol Myers Squibb positions ZENBEXUS against existing multiple myeloma treatments in the relapsed/refractory setting.
Commercialization Strategy
The pace at which Bristol Myers Squibb can integrate ZENBEXUS into treatment protocols, particularly in community care settings.